Kazia Therapeutics reports 2,114,649 ADS (18.5%)

Kazia Therapeutics Ltd reports beneficial ownership of 2,114,649 American Depositary Shares, representing 18.5% of the class as of May 26, 2026.

Rhea-AI Filing Summary

Kazia Therapeutics Ltd reports beneficial ownership of 2,114,649 American Depositary Shares, representing 18.5% of the class as of May 26, 2026. The filing calculates the class base on 11,426,899 ADS outstanding as of March 12, 2026, per the issuer's Form F-3. The schedule lists the reporting person as Jorey Chernett with sole voting and dispositive power over the disclosed ADS.

Insights

Corporate Governance Analyst

Significant single-holder stake disclosed: 18.5% ownership.

The filing shows Jorey Chernett beneficially owns 2,114,649 ADS, equal to 18.5% of the class using an March 12, 2026 outstanding base of 11,426,899 ADS. This is a large, disclosed beneficial position in a single holder.

Concentration of voting power can affect governance outcomes and potential coordination with other holders. Subsequent disclosures or amendments would clarify whether holdings change or if any voting agreements exist; timing not specified in the provided excerpt.

Securities Compliance Specialist

Filing type and calculation method are explicit; disclosure aligns with Schedule 13G/A norms.

The schedule cites the issuer's Form F-3 for the 11,426,899 ADS outstanding figure and provides the Reporting Person's address, citizenship, and voting/dispositive powers. The filing is signed and dated 05/27/2026.

Compliance implications are routine: the amendment updates beneficial ownership data. Any material change in ownership or voting arrangements would typically trigger further amendments per applicable rules.

Key Figures

Beneficial ownership: 2,114,649 shares Percent of class: 18.5% ADS outstanding: 11,426,899 shares

3 metrics

Beneficial ownership 2,114,649 shares ADS owned as of May 26, 2026

Percent of class 18.5% Calculated using ADS outstanding as of March 12, 2026

ADS outstanding 11,426,899 shares Outstanding ADS base as of March 12, 2026 (per Form F-3)

Key Terms

American Depositary Shares (ADS), Schedule 13G/A, Beneficially owned

3 terms

American Depositary Shares (ADS) market

"Title of class of securities: American Depositary Shares"

American depositary shares (ADS) are a way for investors in the United States to buy shares of foreign companies without dealing with the complexities of international markets. They represent ownership in a foreign company's stock and are traded on U.S. exchanges, making it easier and more convenient for Americans to invest internationally. ADSs allow investors to diversify their portfolios with foreign companies while using familiar trading platforms.

Schedule 13G/A regulatory

"(Amendment No. 3 ) KAZIA THERAPEUTICS LTD"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned regulatory

"As of the close of business on May 26, 2026, the Reporting Person beneficially owned 2,114,649 ADS"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Jorey Chernett report in Kazia Therapeutics (KZIA)?

The filing states 2,114,649 ADS, equal to 18.5% of the class. It bases the percentage on 11,426,899 ADS outstanding as of March 12, 2026, per the issuer's Form F-3.

What date is the ownership figure effective in the KZIA Schedule 13G/A amendment?

Ownership is reported as of May 26, 2026. The filing also cites the ADS outstanding base as of March 12, 2026 to calculate the percentage.

Does the filing state who holds voting and dispositive power over the KZIA ADS?

Yes. The filing indicates the Reporting Person, Jorey Chernett, has sole voting and sole dispositive power over 2,114,649 ADS, as shown on the cover page items.

What source does the filing use to calculate the percent ownership for KZIA?

The percent is calculated using the issuer's reported 11,426,899 ADS outstanding figure from the company's Form F-3 filed March 17, 2026, as cited in the Schedule 13G/A.

When was this Schedule 13G/A amendment signed and filed for KZIA?

The signature block shows the Reporting Person signed the amendment on 05/27/2026, and the ownership amount is reported as of 05/26/2026 in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 10:31 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

KAZIA THERAPEUTICS LTD

(Name of Issuer)

American Depositary Shares

(Title of Class of Securities)

48669G105

(CUSIP Number)

05/26/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 48669G105

1

Names of Reporting Persons

Chernett Jorey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,114,649.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,114,649.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,114,649.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

18.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KAZIA THERAPEUTICS LTD
(b)	Address of issuer's principal executive offices: THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE, SYDNEY NSW, C3, 2000
Item 2.
(a)	Name of person filing: Jorey Chernett (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: The principal business address of the Reporting Person is 6222 Indianwood Trail, Bloomfield Hills, MI 48301.
(c)	Citizenship: US.
(d)	Title of class of securities: American Depositary Shares
(e)	CUSIP No.: 48669G105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The aggregate percentage of American Depositary Shares ("ADS") owned by the Reporting Person is calculated based upon 11,426,899 American Depository Shares outstanding as of March 12, 2026 (assuming all outstanding Ordinary Shares were represented by American Depository Shares), as disclosed in the Issuer's Registration Statement on Form F-3, filed with the U.S. Securities and Exchange Commission (the "SEC") on March 17, 2026. As of the close of business on May 26, 2026, the Reporting Person beneficially owned 2,114,649 ADS.
(b)	Percent of class: 18.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chernett Jorey

Signature:	/s/ Jorey Chernett
Name/Title:	Jorey Chernett
Date:	05/27/2026